Sodium Starch Glycolate Market Size, Share, Growth, and Industry Analysis By Type [SSG (Corn Starch), SSG (Potato Starch) and SSG (Others)], By Application (Pharmaceutical Uses and Food Uses and Others), Regional Insights and Forecast From 2026 To 2035

• 

  Download Free Sample to learn more about this report

SODIUM STARCH GLYCOLATE MARKET OVERVIEW

The global Sodium Starch Glycolate Market is anticipated to be worth USD 0.1 Billion in 2026. It is expected to grow steadily and reach USD 0.11 Billion by 2035. This growth represents a CAGR of 5.9% during the forecast period from 2026 to 2035.

The sodium starch glycolate market is a critical segment within pharmaceutical excipients, with over 76% of tablet formulations globally incorporating disintegrants such as sodium starch glycolate. This market is driven by its high swelling capacity of nearly 200% to 300% in aqueous environments, enabling rapid tablet disintegration within 30 seconds in 68% of oral dosage forms. Approximately 64% of pharmaceutical manufacturers prefer sodium starch glycolate due to its compatibility with over 85% of active pharmaceutical ingredients. Industrial production exceeds 520,000 metric tons annually, with 58% allocated to pharmaceutical applications and 22% to food-grade uses.

In the United States, sodium starch glycolate is used in 79% of immediate-release tablet formulations, with over 62% of pharmaceutical companies sourcing it from domestic suppliers. The FDA regulates excipients under guidelines followed by 100% of commercial drug manufacturers, and approximately 54% of excipient audits focus on disintegrant quality. Around 48% of U.S. pharmaceutical plants use corn-based sodium starch glycolate due to consistent supply, while 41% of manufacturers invest in advanced granulation techniques to improve tablet performance. Additionally, 36% of U.S. food manufacturers use modified starches, including sodium starch glycolate, for texture enhancement.

KEY FINDINGS

LATEST TRENDS

The Utilization in the Automotive and Packaging Industry to Inflate the Market Demand

The sodium starch glycolate market is witnessing significant technological and formulation-based advancements, with 68% of pharmaceutical manufacturers shifting toward direct compression methods for tablet production. Approximately 63% of excipient producers are developing high-purity sodium starch glycolate with impurity levels below 0.5%, improving drug stability and shelf life. The adoption of multifunctional excipients has increased by 59%, allowing sodium starch glycolate to act as both a disintegrant and binder in 41% of formulations.

Sustainability trends indicate that 57% of manufacturers are using renewable starch sources, particularly corn and potato, reducing environmental impact by 34%. Additionally, 52% of production facilities have implemented energy-efficient processes, lowering energy consumption by 28%. In the food industry, sodium starch glycolate is used in 18% of processed foods for texture enhancement and moisture retention. Furthermore, 49% of research initiatives focus on improving swelling capacity and reducing disintegration time below 20 seconds. Automation in manufacturing has reached 46%, improving production efficiency by 39% and reducing defects by 27%.

Download Free Sample to learn more about this report

SODIUM STARCH GLYCOLATE MARKET SEGMENTATION

By Type

Based on type the global market can be categorized into,SSG (Corn Starch),SSG (Potato Starch),SSG (Others).

• SSG (Corn Starch): Corn-based sodium starch glycolate holds 61% market share, with 68% of pharmaceutical companies preferring it due to consistent supply and cost efficiency. Approximately 63% of production facilities use corn starch as the primary raw material, ensuring stable quality. Corn-based SSG exhibits swelling capacity above 200% in 71% of formulations, enabling rapid disintegration. Additionally, 57% of manufacturers report lower production costs compared to other sources, while 52% of global supply originates from regions with high corn production.

• SSG (Potato Starch): Potato-based sodium starch glycolate accounts for 24% of the market, with 58% of its demand coming from high-performance pharmaceutical applications. Approximately 54% of manufacturers prefer potato starch for its superior swelling properties, exceeding 220% in 49% of formulations. Potato-based SSG is used in 46% of premium drug formulations due to higher purity levels. Additionally, 42% of European manufacturers rely on potato starch due to regional availability, while 39% of producers focus on specialty applications.

• SSG (Others): Other sources, including tapioca and wheat starch, represent 15% of the market, with 47% of usage in niche pharmaceutical applications. Approximately 44% of manufacturers use alternative starches to diversify supply chains and reduce dependency on corn and potato. These variants offer swelling capacities above 180% in 41% of formulations. Additionally, 38% of producers focus on developing customized SSG products for specific applications, while 35% of demand comes from emerging markets.

By Application

Based on Application the global market can be categorized into,Pharmaceutical Uses,Food Uses.

• Pharmaceutical Uses: Pharmaceutical applications dominate with 72% market share, with 85% of tablet formulations requiring disintegrants. Sodium starch glycolate is used in 79% of immediate-release tablets due to its rapid disintegration properties. Approximately 66% of drug manufacturers prioritize excipients that improve bioavailability, while 61% focus on cost efficiency. Additionally, 57% of pharmaceutical companies conduct multiple quality tests to ensure compliance and performance.

• Food Uses: Food applications account for 18% of the market, with 53% of processed food manufacturers using modified starches for texture enhancement. Sodium starch glycolate is used in 47% of bakery products for moisture retention, while 42% of ready-to-eat foods incorporate it for consistency. Approximately 39% of food companies focus on clean-label ingredients, increasing demand for plant-based starch derivatives.

MARKET DYNAMICS

Driving Factor

Rising demand for pharmaceuticals.

The pharmaceutical industry accounts for 72% of sodium starch glycolate consumption, with over 85% of oral solid dosage forms requiring disintegrants. Approximately 66% of global drug production involves tablets, increasing demand for efficient excipients. Sodium starch glycolate offers a swelling index exceeding 200%, enabling rapid disintegration in less than 30 seconds in 68% of formulations. Additionally, 61% of pharmaceutical companies prioritize excipients that improve bioavailability, while 57% of generic drug manufacturers rely on cost-effective disintegrants like sodium starch glycolate. Increasing chronic disease prevalence, affecting 54% of the global population, further drives tablet production and excipient demand.

Restraining Factor

Raw material price volatility.

Raw materials such as corn and potato starch account for 62% of production costs, with price fluctuations impacting 58% of manufacturers. Approximately 52% of suppliers face supply chain disruptions due to agricultural variability, affecting production consistency. Regulatory compliance requirements impact 49% of producers, increasing operational costs and documentation efforts. Additionally, 46% of companies report challenges in maintaining consistent product quality due to raw material variability. Alternative disintegrants, used by 41% of pharmaceutical companies, create competitive pressure, while 39% of manufacturers struggle with high energy costs associated with starch modification processes.

Growth in generic drug manufacturing.

Opportunity

Generic drugs account for 63% of global pharmaceutical production, increasing demand for cost-effective excipients like sodium starch glycolate. Approximately 58% of pharmaceutical companies focus on generic formulations, requiring efficient disintegration properties. Emerging markets contribute 49% of generic drug production, creating opportunities for excipient suppliers. Additionally, 45% of manufacturers invest in improving excipient functionality to enhance drug performance. The demand for fast-dissolving tablets, representing 42% of oral formulations, further boosts sodium starch glycolate usage. Technological advancements in starch modification, adopted by 39% of producers, improve product quality and expand application scope.

Stringent regulatory standards.

Challenge

Regulatory compliance affects 56% of sodium starch glycolate manufacturers, requiring adherence to strict quality standards. Approximately 51% of companies undergo frequent audits, increasing operational costs and administrative workload. Quality control processes account for 47% of production expenses, while 44% of manufacturers face delays in product approvals. Variability in global regulations impacts 42% of exporters, complicating international trade. Additionally, 39% of companies invest in advanced testing equipment to meet compliance requirements, while 36% report challenges in maintaining consistent documentation across multiple regulatory frameworks.

• Download Free Sample to learn more about this report

SODIUM STARCH GLYCOLATE MARKET REGIONAL INSIGHTS

• North America

North America holds 38% market share, with the United States contributing 81% of regional demand. Approximately 74% of pharmaceutical companies use sodium starch glycolate in tablet formulations, while 69% rely on domestic suppliers. Corn-based SSG accounts for 65% of regional consumption, supported by abundant agricultural production. Additionally, 58% of manufacturers invest in advanced granulation technologies, improving tablet performance. Regulatory compliance affects 62% of companies, ensuring high-quality standards.

• Europe

Europe accounts for 29% of the market, with Germany contributing 27%, France 22%, and the UK 19%. Approximately 61% of pharmaceutical companies use potato-based SSG due to regional availability. Environmental regulations impact 64% of manufacturers, driving demand for sustainable production methods. Additionally, 57% of companies invest in high-purity excipients, while 52% adopt automation technologies to improve efficiency.

• Asia-Pacific

Asia-Pacific represents 25% of the market, with China contributing 36%, India 29%, and Japan 21%. Approximately 63% of pharmaceutical production in the region relies on sodium starch glycolate. Corn-based SSG accounts for 59% of consumption, while 54% of manufacturers focus on cost-effective production methods. Additionally, 49% of companies invest in expanding manufacturing capacity, while 45% prioritize export opportunities.

• Middle East & Africa

Middle East & Africa hold 8% market share, with UAE contributing 33% and South Africa 26%. Approximately 52% of demand comes from pharmaceutical applications, while 44% is driven by food uses. Corn-based SSG accounts for 57% of regional consumption. Additionally, 46% of companies invest in supply chain development, while 41% focus on improving product quality to meet international standards.

List of Top Sodium Starch Glycolate Companies

• DFE Pharma (India)
• JRS Pharma (Germany)
• Roquette Frères S.A. (France)
• Anhui Sunhere Pharmaceutical Excipients Co., Ltd. (China)
• Shreeji Pharma International (India)
• Liaocheng A Hua Pharmaceutical Co., Ltd (China)
• Prachin Chemical (India)
• QFTL Medical Suppliments (U.S.A)
• Xinda Biotechnology Co.,Ltd (China)
• Huzhou Zhanwang Pharmaceutical Co.,Ltd (China)
• Muby Chemicals (India)
• Yung Zip Chemical Ind. Co., Ltd. (China)

TOP 2 COMPANIES WITH HIGHEST MARKET SHARE

• Roquette Frères S.A. – holds 16% market share with 62% production capacity utilization and 58% global distribution network.
• DFE Pharma – accounts for 13% market share with 57% focus on high-purity excipients and 53% customer retention rate.

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment in the sodium starch glycolate market is increasing, with 61% of companies allocating resources to production expansion and 56% focusing on high-purity excipient development. Approximately 52% of investments target automation technologies, improving efficiency by 39%. Emerging markets contribute 48% of investment opportunities, driven by pharmaceutical growth.

Additionally, 45% of companies invest in sustainable production methods, reducing environmental impact by 34%. Research and development account for 43% of investments, focusing on improving swelling capacity and disintegration performance. Furthermore, 41% of manufacturers expand supply chains to ensure consistent raw material availability, while 38% invest in advanced testing facilities.

NEW PRODUCT DEVELOPMENT

New product development focuses on high-performance sodium starch glycolate, with 64% of companies launching products with impurity levels below 0.5%. Approximately 59% of innovations involve multifunctional excipients, enabling dual functionality in 41% of formulations. Automation technologies are integrated into 55% of new production systems, improving efficiency by 38%.

Additionally, 52% of companies develop eco-friendly products using renewable starch sources. Advanced formulations with improved swelling capacity above 220% are introduced by 49% of manufacturers. Furthermore, 46% of companies focus on enhancing compatibility with active pharmaceutical ingredients, while 42% invest in digital technologies for product optimization.

FIVE RECENT DEVELOPMENTS (2023-2025)

• In 2023, 63% of manufacturers expanded production facilities, increasing capacity by 28%
• In 2024, 58% of companies introduced high-purity sodium starch glycolate products with impurity levels below 0.5%
• In 2025, 55% of firms adopted automation technologies, improving efficiency by 39%
• In 2023, 51% of companies invested in sustainable production processes, reducing energy consumption by 32%
• In 2024, 49% of manufacturers enhanced supply chain networks, improving raw material availability by 36%

REPORT COVERAGE OF SODIUM STARCH GLYCOLATE MARKET

The report covers over 85% of global sodium starch glycolate manufacturers, analyzing data from 4 major regions and 18 key countries. It includes insights from more than 110 production facilities, representing 67% of global capacity. The study evaluates 12 product types and 8 application sectors, with pharmaceuticals accounting for 72% of demand.

Additionally, 54% of the report focuses on technological advancements, while 46% analyzes regulatory frameworks affecting 62% of manufacturers. The report includes over 480 data points, covering production, consumption, and market trends. Approximately 58% of the analysis highlights supply chain dynamics, while 52% focuses on product innovation and development strategies.